会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 25. 发明授权
    • 몰루긴을 함유하는 항암용 조성물
    • 包含乳腺癌治疗癌症的组合物
    • KR101322664B1
    • 2013-10-30
    • KR1020130036604
    • 2013-04-04
    • 충남대학교산학협력단
    • 정혜광김형균나민균
    • A61K31/352A61K31/35A61P35/00
    • PURPOSE: An anticancer composition comprising mollugin is provided to use as a therapeutic agent for cancer patients who have tolerance to existing anticancer drugs by having an excellent effect of killing multidrug resistance cancer cells. CONSTITUTION: An anticancer composition having an effect of killing multidrug resistance cancel cells comprises mollugin of chemical formula 1. The multidrug resistance cancer cells are cancer cells which express multidrug resistance 1 (MDR1). The composition increases activation of AMP-activated protein kinase (AMPK). An anticancer drung is added to the composition. The mollugin is comprised in the composition in a ratio of 0.001-99 wt%.
    • 目的:提供包含蜕皮素的抗癌组合物,作为对现有抗癌药物具有耐受性的癌症患者的治疗剂,具有杀死多药耐药性癌细胞的优异效果。 构成:具有杀伤多药耐药性细胞杀伤作用的抗癌组合物包括化学式1的蜕皮。多药耐药性癌细胞是表达多药耐药性1(MDR1)的癌细胞。 组合物增加AMP活化蛋白激酶(AMPK)的活化。 向组合物中加入抗癌剂。 该组合物以0.001-99重量%的比例包含该组合物。
    • 29. 发明授权
    • 몰루긴을 함유하는 유방암 또는 난소암의 예방 또는 치료용 조성물
    • 包含乳液治疗或预防乳腺癌和卵巢癌的组合物
    • KR101322661B1
    • 2013-10-30
    • KR1020130026035
    • 2013-03-12
    • 충남대학교산학협력단
    • 정혜광김형균나민균
    • A61K31/352A61K31/35A61P35/00
    • PURPOSE: A composition for preventing or treating breast cancer and ovarian cancer, comprising mollugin is provided to have excellent effect of killing cancer cells. CONSTITUTION: A composition for preventing or treating breast cancer and ovarian cancer comprises mollugin of chemical formula 1. The breast cancer or ovarian cancer is a cancer that the gene of human epidermal growth factor receptor 2 (HER2) is overexpressed. The composition suppresses HER2/Akt/sterol regulatory element binding proteins (SREBPs). A pharmaceutical composition for preventing or treating breast cancer and ovarian cancer comprises the mollugin and a pharmaceutical exipient. The mollugin in the pharmaceutical composition is comprised in a ratio of 0.001-99.9 wt%.
    • 目的:提供一种用于预防或治疗乳腺癌和卵巢癌的组合物,其包含蜕皮素以具有极好的杀死癌细胞的作用。 构成:用于预防或治疗乳腺癌和卵巢癌的组合物包括化学式1的蜕皮。乳腺癌或卵巢癌是人表皮生长因子受体2(HER2)的基因过表达的癌症。 该组合物抑制HER2 / Akt /甾醇调节元件结合蛋白(SREBPs)。 用于预防或治疗乳腺癌和卵巢癌的药物组合物包括蜕皮剂和药物制剂。 药物组合物中的蜕皮剂的含量为0.001-99.9重量%。
    • 30. 发明授权
    • 만병초로부터 분리된 트리테르페노이드계 화합물을 함유하는 대사성 질환의 예방 또는 치료용 조성물
    • 包含用于治疗或预防代谢性疾病的三磷酸胞苷分离的罗丹明氯氰菊酯的组合物
    • KR101278273B1
    • 2013-06-25
    • KR1020120104871
    • 2012-09-21
    • 충남대학교산학협력단
    • 나민균
    • A61K31/56A61K31/575A61K31/015A61P3/00
    • A61K31/56A61K36/45A61K2236/333Y10S514/866Y10S514/909
    • PURPOSE: A composition containing triterpenoids isolated from Rhododendron brachycarpum for preventing or treating metabolic diseases is provided to suppress protein tyrosine phosphatase 1B(PTP1B), and to suppress or treat diabetes or obesity. CONSTITUTION: A composition for preventing or treating obesity or diabetes contains one or more kinds of triterpenoids selected from the group consisting of rhododendric acid A(compound 1), 2alpha, 3alpha, 23-trihydroxyursa-12,20(30)-dien-28-oic acid(compound 3), and actinidic acid(compound 5) denoted by chemical formulas 1 and 3, which are isolated from Rhododendron brachycarpum. A method for isolating rhododendric acid A denoted by chemical formula 1 comprises: a step of extracting Rhododendron brachycarpum leaves with water, C1-C4 alcohols, or a mixture thereof; a step of sequentially fractioning the extract with n-hexane, chloroform, and ethyl acetate; and a step of isolating the compound denoted by the chemical formula 1 from the chloroform fraction using chromatography. [Reference numerals] (AA) Compound 1; (BB) Compound 3; (CC) Compound 5
    • 目的:提供一种含有杜鹃花分离的三萜类化合物用于预防或治疗代谢疾病的组合物,用于抑制蛋白酪氨酸磷酸酶1B(PTP1B),抑制或治疗糖尿病或肥胖症。 构成:用于预防或治疗肥胖症或糖尿病的组合物含有一种或多种选自杜鹃花酸A(化合物1),2α,3α,23-三羟基己二醇-12,20(30) - 二烯-28的三萜类化合物 (化合物3)和由化学式1和3表示的由杜鹃花(Bravycycarpum)分离的锕系酸(化合物5)。 由化学式1表示的分离杜鹃花酸A的方法包括:用水,C1-C4醇或其混合物提取杜鹃花叶柄的步骤; 用正己烷,氯仿和乙酸乙酯依次分级提取物的步骤; 以及使用色谱法从氯仿级分中分离由化学式1表示的化合物的步骤。 (AA)化合物1; (BB)化合物3; (CC)化合物5